Forbes website biotechnology industry reporter Luke Timmerman hears various types of stories every day. For example, the establishment of partnerships between enterprises (pharmaceutical companies need new products from small enterprises, small enterprises need funds from large pharmaceutical companies), the publication of clinical trial results, and the mutual supervision of enterprises and investors. Here are Luke Timmerman's observations and looking forward to the five "Big Idea" trends that the biotech industry is looking forward to in 2017. 1) New ideas for the treatment of Alzheimer's disease (Alzheimer's disease) Although Alzheimer's disease is only the tip of the iceberg of many human diseases, it will become an important burden in national health care as the baby boomers grow up. The analysis predicts that by 2040, a quarter of the world's medical expenses will be used to treat Alzheimer's disease. However, the pharmaceutical industry has yet to find an effective way to treat Alzheimer's disease. Billions of dollars are used to develop targeted drugs to remove the accumulation of beta amyloid plaques, which blur memories and cognition as they age. Fortunately, we have seen alternative scientific methods emerge, such as Yumanity Therapeutics in Cambridge, Massachusetts, raising $45 million to create new drug developments for Alzheimer's disease and other neurodegenerative diseases. The model; Annexon Biosciences in the San Francisco area raised $44 million to stop the immune system against Alzheimer's disease by clearing the synapses needed by functional neurons. Despite the failure of many Alzheim drug developments in the early stage, due to the urgent needs of Alzheimer's patients and the huge market temptation, Lilly's anti-amyloid β-protein monoclonal solanezumab died and was revived. The drug factory is treating Alzheimer's disease. In terms of strategy, it also opened up the strategy of putting eggs in multiple baskets. 2) Make scientific observation as vivid as watching a movie Currently, many drug discoveries are still based on static images of molecular targets, and chemists hope to create compounds that target specific targets. However, these targets flow in real life, and their shape changes make it difficult for compounds to bind to them. If you are no longer a static image based on molecular targets, but you can see a series of photos like "movies", you will know more clearly how the protein targets fold at different locations. In this way, you'll get a deeper understanding of how a drug can better bind to a particular target. Currently, two companies in the Boston area, Relay Therapeutics and Morphic Therapeutic, have raised more than $50 million to find new drugs based on the basic principles of molecular action to find more effective ligands that bind to protein-binding pockets. . This is a bold idea, such as Pfizer, GlaxoSmithKline, Aibowei and Sanshi Ventures are closely watching. Surgical Tape,Adhesive Flexible Tape,Waterproof Surgical Tape,Breathable Surgicaltape Zhende Medical Co.,Ltd , https://www.zdmedicalproducts.com